Innovent Biologics’ dual GCG/GLP-1RA, Xinermei (mazdutide) has met its primary endpoint in the head-to-head Phase III DREAMS-3 study, significantly improving blood glucose control and weight loss over ...

BridgeBio’s stock was up after it announced the Phase III trial met its endpoints. Image credit: saepul_bahri / Shutterstock.com. BridgeBio Pharma will seek US approval of its limb-girdle muscular ...

Inhibrx’s DR5-targeting antibody has more than doubled PFS compared with placebo in a Phase II trial in chondrosarcoma, a rare bone cancer with no approved targeted therapies. Image credit: Kateryna ...

The data was announced during the 2025 North American Menopause Society (NAMS) Annual Meeting. Image credit: shisu_ka / Shutterstock.com. Entera Bio’s osteoporosis candidate for postmenopausal women ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Electra is assessing ELA026 for haematologic cancers, following promising initial clinical data. Credit: Motortion Films / Shutterstock.com. Electra Therapeutics has raised $183m in an oversubscribed ...

Neuphoria Therapeutics’ lead candidate, BNC210, has failed to show efficacy in the Phase III AFFIRM-1 trial in social anxiety disorder. Image credit: Blueastro via Shutterstock.com. Neuphoria ...

Roche’s Elecsys pTau217 assay is intended to be used to help identify amyloid pathology, a feature of Alzheimer’s disease. Image Credit: Jonathan Weiss / Shutterstock. The US Food and Drug ...

Dash Solutions has introduced dashClinical, a payment solution that provides real-time, secure payments to clinical trial ...

Johnson & Johnson’s targeted therapeutic combination, Tecvayli-Darzalex Faspro, performed better than investigator’s choice standard of care in a Phase III trial recruiting patients with R/R multiple ...

The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...